Study of d-MAPPS™ Ophthalmic Solution, Safety, Tolerability, and Efficacy in the Treatment of Chronic Ocular Graft-Versus-Host Disease (oGVHD)

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(6 sites)

United States

Beverly Hills Institute of Ophthalmology, Beverly Hills, California

Beach Eye Medical Group, Huntington Beach, California

Regenerative Ocular Immunobiologics, LLC., Palm Harbor, Florida

Glenn Eye Center, Lexington, Kentucky

Eyewell, LLC., Boston, Massachusetts

BostonSight, Boston, Massachusetts